MMPSense(TM) 750 FAST is Presented at AACR 100th Annual Meeting
BEDFORD, Mass., April 20 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the introduction of its new FAST ("Fluorescent Activatible Sensor Technology") imaging agent platform for advanced imaging of key disease-associated biomarkers and drug response in vivo. Newly developed by VisEn Medical, FAST imaging agents are smaller molecule, biocompatible, activatible fluorescent agents that combine increased biomarker specificity with accelerated pharmacokinetics for advanced measurement and monitoring of key disease biomarkers in vivo. The new MMPSense 750 FAST, the first of the FAST agents to be launched by VisEn, was described today in a scientific poster presentation entitled "In vivo imaging of treatment effects using a novel near-infrared labeled agent: MMPSense 750 FAST", at the annual Scientific Sessions of the AACR (American Association of Cancer Research) 100th Annual Meeting 2009 in Denver, CO by Jeffrey D. Peterson, Ph.D., Vice President of Applied Biology at VisEn.
At the AACR 100th Annual Meeting, the Peterson et al study demonstrated the performance of MMPSense 750 FAST as a fast-acting, near-infrared imaging agent to measure tumor MMP activity in vivo and monitor treatment efficacy. In the study, administration of the agent allowed the non-invasive measurement of MMP inhibition using two different chemotherapy regimes. Using the VisEn FMT 2500(TM) quantitative tomography system, tumor fluorescence due to in vivo activation of the agent was clearly detectable as early as 4 hours after injection of the agent with the signal maximizing between 6 and 24 hours. By 96 hours, only 15% of the signal was still present in tumors. "Our study utilized MMPSense 750 FAST as a mechani
|SOURCE VisEn Medical Inc.|
Copyright©2009 PR Newswire.
All rights reserved